Details for Patent: 7,425,637

Which drugs does patent 7,425,637 protect, and when does it expire?

Patent 7,425,637 protects KOSELUGO and is included in one NDA.

This patent has one hundred and twenty-three patent family members in thirty-four countries.

Summary for Patent: 7,425,637

Patent landscape, scope, and claims:

Title:	N3 alkylated benzimidazole derivatives as MEK inhibitors
Abstract:	Disclosed are compounds of the Formula I ##STR00001## and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Inventor(s):	Wallace; Eli M. (Lyons, CO), Lyssikatos; Joseph P. (Superior, CO), Marlow; Allison L. (Boulder, CO), Hurley; T. Brian (Boulder, CO)
Assignee:	Array BioPharma Inc. (Boulder, CO)
Application Number:	11/061,336
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,425,637

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No				Y
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-002	Apr 10, 2020		RX	Yes	Yes				Y

International Family Members for US Patent 7,425,637

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1482932		PA2019007	Lithuania
European Patent Office	1482932		LUC00100	Luxembourg
European Patent Office	1482932		300974	Netherlands
European Patent Office	1482932		2019C/510	Belgium